Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 2;21(1):10.
doi: 10.1007/s11906-019-0914-2.

Autoimmune Disease-Associated Hypertension

Victoria L Wolf  1 , Michael J Ryan  2   3
Affiliations
Review

Autoimmune Disease-Associated Hypertension

Victoria L Wolf et al. Curr Hypertens Rep. .

Abstract

Purpose of review: To highlight important new findings on the topic of autoimmune disease-associated hypertension.

Recent findings: Autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis are associated with an increased risk for hypertension and cardiovascular disease. A complex interaction among genetic, environmental, hormonal, and metabolic factors contribute to autoimmune disease susceptibility while promoting chronic inflammation that can lead to alterations in blood pressure. Recent studies emphasize an important mechanistic role for autoantibodies in autoimmune disease-associated hypertension. Moving forward, understanding how sex hormones, neutrophils, and mitochondrial dysfunction contribute to hypertension in autoimmune disease will be important. This review examines the prevalent hypertension in autoimmune disease with a focus on the impact of immune system dysfunction on vascular dysfunction and renal hemodynamics as primary mediators with oxidative stress as a main contributor.

Keywords: Autoimmunity; Hypertension; Inflammation; Lupus; Renal hemodynamics; Vascular function.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Dr. Ryan reports grants from Veterans Affairs, grants from NIH, grants from AHA, during the conduct of the study. Dr. Wolf declares no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

    1. Rees F, DohertyM,Grainge MJ, Lanyon P, ZhangW. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(11):1945–61. 10.1093/rheumatology/kex260. - PubMed
    1. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605–620. doi: 10.1038/nrrheum.2016.137. - DOI - PubMed
    1. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013–2015. MMWR Morb Mortal Wkly Rep. 2017;66(9):246–253. doi: 10.15585/mmwr.mm6609e1. - DOI - PMC - PubMed
    1. Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J Autoimmun. 2017;82:1–12. doi: 10.1016/j.jaut.2017.05.008. - DOI - PubMed
    1. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007;46(9):1477–1482. doi: 10.1093/rheumatology/kem169. - DOI - PubMed

Publication types

MeSH terms